ANS Biotech launches a new iatrogenic neuropathic pain model.
In France, the total number of new cancer cases is estimated at about 400,000 each year.
Chemotherapy-induced peripheral neuropathy (CIPN) occurs frequently in patients treated with different anti-cancer agents, such as oxaliplatin (85%-95%).
Oxaliplatin is a third-generation platinum-based chemotherapy drug widely used in the treatment of advanced metastatic colorectal cancer (45,000 new cases/year in France) but its use is limited by a cumulative and chronic hematotoxicity, nephrotoxicity and neurotoxicity. The latter, particularly debilitating, is difficult to assess and treatments remain empirical and ineffective. Clinical signs include dysesthesia (pain caused by stimulus or contact) and paresthesia (tingling, burning) in the distal extremities, spontaneous pain and loss of sensation.
The limitation of current iatrogenic pain treatments encourage companies like ANS Biotech to develop relevant preclinical models.
In the particular case of oxaliplatin, chronic peripheral sensory neuropathy is induced by repeated injections of oxaliplatin (4 mg/kg) twice a week during 3 consecutive weeks.
Specialized in Services and R&D in pharmacology of pain, ANS Biotech has developed a a model of hypersensitivity to cold induced by Oxaliplatin.
This model enables exploring significant behavioural nociceptive signs and is consistent with clinical symptoms increasing progressively in duration and severity with repetition of treatment-cycles. It is useful to evaluate the antalgic effects of new compounds provided by its customers on oxaliplatin-induced chronic painful symptoms.